Posted inBiotechnology
Former Spero execs fined by SEC over antibiotic efficacy claims
Two former executives from Spero Therapeutics have agreed to settle with the Securities and Exchange Commission for allegedly misleading investors…
Posted inBiotechnology
Tanabe Pharma’s oral drug scores in ph. 3 rare disease study, though details remain in the dark
Tanabe Pharma America’s small molecule designed to boost melanin production has hit the main goal of a phase 3 trial for…
Posted inBiotechnology
Pfizer pens $530M deal to use Novavax’s vaccine adjuvant tech on 2 programs
Pfizer is paying $30 million to use Novavax’s adjuvant technology to improve the efficacy of two of the Big Pharma’s…
Posted inBiotechnology
Vessels in Liver Cancer: A Unique Metastatic Route
A recent study published in J Transl Med has brought to light a groundbreaking finding in the realm of hepatocellular…
Posted inBiotechnology
Boundless finally gives up on combo treatment of 2 unimpressive cancer drugs
Boundless Bio has finally given on its hopes on finding redemption for two solid tumor drugs that had both come…
Posted inBiotechnology
Burnout Among Medical Insurance Specialists in Guangxi
In recent years, the healthcare landscape in China has undergone significant transformations, particularly within public hospitals. A thought-provoking new study…
Posted inBiotechnology
Burial Effects on Decomposition: Porcine Soil Study
In the realm of forensic science, decompositional analysis serves as a cornerstone for unraveling the mysteries that follow death. A…
Posted inMedical Technology
Bristol Myers Squibb taps Microsoft’s AI detection network for speedy lung cancer diagnosis
Microsoft and Bristol Myers Squibb have signed a new pact aimed at identifying lung cancer cases more quickly. The U.S.…
Posted inBiotechnology
Assessing Superheroes Social Skills in Autistic Preschoolers
In a groundbreaking study published in the Journal of Autism Spectrum Disorders, researchers have delved into the efficacy of a…
Posted inBiotechnology
Merck-Moderna cancer vaccine sustains 49% melanoma risk reduction at 5 years
Adding Merck & Co. and Moderna’s vaccine candidate to Keytruda has continued to cut the risk of cancer recurrence or death…